RPL17 and melanoma: Growth of subcutaneously implanted melanoma (B16F10) and pancreatic cancer (MT5) in C57BL/6 mice was monitored every day following daily administration of 10ug VIPhyb (subcutaneously) starting from day -1 and/or 200ug of IgG2a or anti-PD-1 antibody (intraperitoneally) on day -1 and every 3 days thereafter.